Company intelligence / Profile preview
Spherium Biomed
Esplugues de Llobregat, Barcelona, Spainabg-ip.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Positive results in Phase I/IIa clinical trial for Mucomel for oral mucositis in head and neck cancer patients treated with chemo and radiotherapy. Mucomel reduces the incidence of severe mucositis to almost half of patients and shortens its duration. Also completed Phase IIa for Cyclatop (topical cyclosporine) for atopic dermatitis.
- Therapeutic areas
- GastroenterologyPsychiatryCardiovascularNephrologyImmunologyDermatologyRare DiseasesNeurology
- Modalities
- Small molecule drugsSynthetic peptidesRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Ferrer
Beyond the preview
Go deeper on Spherium Biomed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spherium Biomed.